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ABSTRACT
Colorectal cancer (CRC) is the fourth most common cancer in worldwide. In 
the last 10 years, the mortality rate of CRC decreased by more than 20% and 
5-year survival remains approximately 60% due to the rising developments in 
diagnostic techniques and optimization of surgical, neoadjuvant and palliative 
therapies. We reported a case of 80-year-old woman with diarrhea, blood in the 
stool and weight loss for a year. The patient was diagnosed with colonic polyp 
eight years ago. In double-contrast barium enema (DCBE) showed filling defects 
in sigmoid with pedunculated form. Optical colonoscopy demonstrated tumor 
in sigmoid. Computed tomography (CT) abdomen showed circumferential 
thickening and luminal narrowing of sigmoid colon with stranding of the 
serosa and mesenteric fat as well as enlarge pericolic nodes without distant 
metastasis. Based on American Joint Committee on Cancer criteria the stage was 
T3N1M0. From histopathological diagnosis, the tumor was well differentiated 
adenocarcinoma. We concluded as unresectable adenocarcinoma colorectal. 
Patient received transcatheter arterial chemoinfusion (TACI) with oxaliplatin 
and bevacizunab in three courses every 2 months. After first TACI, symptoms 
and patient’s performance status improved without systemic side effects. 
Arteriography imaging showed decrease in tumor staining after third TACI. 
CT evaluation showed a significant decrease of tumor size, without nodal 
and distant metastasis.In this case, TACI treatment with oxaliplatin and 
bevacizumab in unresectable adenocarcinoma colorectaldemonstrated 
improvement of patient’s performance status, partial response, decrease stage 
and symptoms, without systemic side effects. It is proven that TACI treatment 
may be an effective palliative therapy for unresectable colorectal cancer. 
Further studies should be performed to verify these findings.We reported a 
case of a woman with unresectable adenocarcinoma colorectal showed good 
results after received TACI treatment. 
ABSTRAK
Kanker kolorektal (KKR) adalah kanker paling banyak keempat di seluruh 
dunia. Dalam 10 tahun terakhir, angka kematian KKR menurun lebih dari 
20% dan harapan hidup 5 tahun tetap sekitar 60% karena meningkatnya 
perkembangan teknik diagnostik dan optimalisasi teknik bedah, terapi 
neoadjuvant dan paliatif.Kami melaporkan kasus wanita berusia 80 tahun 
dengan keluhan diare, darah dalam tinja dan penurunan berat badan 
selama setahun. Pasien didiagnosis polip kolon delapan tahun lalu. Pada 
double-contrast barium enema (DCBE) tampak filling defect pada sigmoid 
dengan bentuk pedunculated. Colonoscopy menunjukkan tumor di sigmoid. 
Computed tomography (CT)abdomen tampak penebalan sirkumferensial dan 
penyempitan lumen pada sigmoid, dengan fat stranding pada lapisan serosa 
dan mesenterika serta pembesaran limfonodi perikolon tanpa metastasis 
jauh. Menurut kriteria American Joint Committee on Cancer stadium nya 
adalah T3N1M0. Diagnosis histopatologi menunjukkanadenocarcinoma 
diferensiasi baik. Kami simpulkan sebagai unresectable adenocarcinoma 
colorectal. Pasien menjalani terapi transcatheter arteri chemoinfusion (TACI) 
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dengan oxaliplatin dan bevacizunab dalam tiga prosedur setiap dua bulan. 
Setelah TACI pertama, gejala dan status kinerja pasien membaik tanpa efek 
samping sistemik. Pencitraan arteriografi menunjukkan penurunan tumor 
stainingsetelah TACI ketiga. Hasil evaluasi CT menunjukkan penurunan 
yang signifikan pada ukuran tumor, tidak ada nodal metastasis maupun 
dan metastasis jauh.Pada kasus ini, terapi TACI dengan oxaliplatin dan 
bevacizumabpada unresectable adenocarcinoma colorectal menunjukkan 
peningkatan status kinerja pasien, partial response,penurunan gejala dan 
stadium kanker, tanpa efek samping sistemik. Ini membuktikan bahwa 
terapi TACI mungkin dapat menjadi terapi paliatif yang efektif untuk 
unresectable adenocarcinoma colorectal. Studi lebih lanjut harus dilakukan 
untuk memverifikasi temuan ini.Kami melaporkan kasus seorang wanita 
dengan unresectable adenocarcinoma colorectal yang menunjukkan hasil 
yang baik setelah menerima terapi TACI.
INTRODUCTION
Colorectal cancer (CRC) is the third 
most common malignant diagnosis and 
the fourth most common cause of cancer 
deaths in the world, accounting for about 
1.4 million new cases and nearly 693,900 
deaths by 2012.1Recently, the CRC became 
a public health problem in Indonesia 
due to it ranked third most of all cancers 
diagnosed with an incidence rate of 19.1 
in men and 15.6 in women per 100,000 
inhabitants.2 The mortality rate among 
Indonesian CRC was 18,958 in 2012. This 
high incidence and mortality are due to 
the lack of early detection and public 
awareness against CRC.3
In the past 10 years the mortality 
rate of CRC has declined by more 
than 20% due to the increasing 
development of diagnostic techniques 
and optimization of surgical techniques, 
neoadjuvant and palliative therapy.4 
The imaging modalities used in current 
CRC management are varied and 
heterogeneous in many countries and 
health institutions.4The recommendation 
of CRC therapy depends on several factors 
such as cancer stage, histopathology, 
possible side effects, patient condition 
and patient preference.5 Chemotherapy 
can be performed with the minimally 
invasive procedure of transcatheter 
arterial chemoinfusion (TACI), by 
infusion of chemotherapy drug in 
arterial feeding that supplies blood to 
the tumor, which aims to maximize the 
concentration and uptake of drugs in 
the target organ and minimize systemic 
toxicity.6
In the last decade, the life expectancy 
of CRC patients has increased worldwide.7 
In Asia the life expectancy of 5 years is 
about 60%.7 It is related to the increased 
early detection and progress on the 
handling of the CRC.7In this case report, 
we reported the case of a woman with 
unresectable adenocarcinoma colorectal 
who underwent TACI therapy. 
CASE REPORT
An 80-year-old woman came with 
bowel complaints of bloody, fresh red, 
slimy and smelly with bowel habit 
disorders since approximately one 
year. Patient experienced weight loss 
in the past year. Patient had a habit of 
eating fatty foods but lacking fiber-
feeding foods. Patienthad no smoking or 
drinking habits. Patient had a history of 
non-specific chronic proctitis with colon 
polyp eight years ago. In the family there 
was no one suffered the CRC.
On the DBCE examination, we found 
a filling defect on the sigmoid with a form 
of pedunculated (valve phenomenon) 
(FIGURE 1). Further recommendations 
for the examination are colonoscopy 
and anatomical pathology biopsy of the 
tumor. The colonoscopy examination 
result was a tumor in sigmoid pars 
proximal with diverticulitis (FIGUE 
2a), and the result of biopsy was a well 
differentiated adenocarcinoma (FIGURE 
2b).
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FIGURE 1. DBCE shows a filling defect on a sigmoid with a pedunculated 
form (valve phenomenon). A)  left oblique projection; B) 
lateral projection.
A B
FIGURE 2. A) Colonoscopy: tumors in the proximal pars sigmoid with 
diverticulitis; B) pathology anatomy: adenocarcinoma well 
differentiation.
Furthermore, CT scan abdomen 
was performed for tumor staging 
enforcement which resulted in 
circumferential thickening and luminal 
narrowing of the sigmoid colon of 9.1 x 
8.3 x 7.4 cm, with fat stranding of serous 
and mesenteric lining and pericolone 
lymph node enlargement without 
distant metastasis (FIGUE 3). From these 
results it was concluded that this patient 
was in T3N1M0 stage IIIB based on AJCC. 
The patient refused to be treated with 
surgery and the tumor was considered as 
a case of unresectable adenocarcinoma 
colorectal, therefore it was decided to be 
treated with TACI procedure.
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FIGURE 3. Abdominal CT scan shows circumferential thickening and luminal 
narrowing of the sigmoid colon of size 9.1 cm x 8.3 cm x 7.4 cm, 
with fat stranding on serous and mesenteric layers (red arrows) 
and pericolon lymph nodes (white arrows) without distant 
metastasis. A) axial projection; B) coronal projection; C) sagittal 
projection.
The patient received TACI treatment 
in three courses every two months. 
The TACI procedure was performed by 
introducing the Simons-2 5Fr catheter 
via the inferior mesenteric artery of 
the inferior arteriography, in which 
the inferior mesenteric artery appears 
inferior artery as an arterial feeding of a 
tumor characterized by a hypervascular 
staining tumor in the rectosigmoid 
region. Then infusion of oxaliplatin 
50 mg and bevacizumab 100 mg were 
administered.
After the first TACI procedure, 
symptoms and patient performance 
status improved without systemic side 
effects. Serial arteriography showed 
a decrease in staining tumor after the 
third TACI procedure (FIGURE 5). While 
in the CT scan evaluation showed a 
significant decrease in tumor size to 2.13 
x 4.92 x 4.35 cm, without metastatic or 
metastatic nodal and distant metastasis, 
after re-staging the stage was declined 
to T3N0M0 stage IIA (FIGURE 5). From 
these results it was concluded that TACI 
treatment response in this case was a 
decline in stage and partial response 
according to RECIST criteria.
FIGURE 4. Arteriography shows decreased staining and vascularization tumors in 
feeding the tumor artery (yellow circle) from the first TACI to the third TACI.
Third TACISecond TACIFirst TACI
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FIGURE 5. CT Scan Abdominal evaluation, before TACI size 9.1 cm x 
8.3 cm x 7.4 cm (red arrow) accompanied by pericolon 
lymph nodes (white arrow), After third TACI procedures 
showed a significant reduction in tumor size to 2.13 cm 
x 4.92 cm x 4.35 cm, no metastatic or distant metastatic 
nodal.
REVIEW OF COLORECTAL CANCER 
Risk factors
The risk factor of CRC is divided 
into two factors that unmodifiable 
and modifiable. Risk factors that 
unmodifiable are a history of cancer 
or colorectal adenoma polyps in 
individuals and/or families, a history of 
chronic inflammatory bowel disease, 
inherited genetic factors including 
familial adenomatous polyposis (FAP) 
and hereditary nonpolyposis colorectal 
cancer (HNPCC) also called Lynch 
syndrome.8 Risk factors that can be 
modified are the limitation of activity, 
obesity, high consumption of red meat, 
smoking and alcohol consumption 
habits.8
Clinical symptoms
The characteristics of clinical 
symptoms of CRC may be the occurrence 
of intestinal obstruction, hemorrhage 
(hematochezia, enterorrhagia), changes 
in bowel habits, and systemic effects 
such as significant weight loss.9 Classical 
symptoms of CRC include constipation, 
blood in the stool, decreased caliber, 
appetite, weight loss, nausea and / or 
vomiting.10,11
Pathogenesis
CRCs occur as a result of genetic defects 
and molecular abnormalities associated 
with the formation and progression of 
cell growth. The change from normal 
colonocytes to adenomatous tissue and 
eventually colorectal carcinoma induces 
a number of mutations that accelerate 
cell growth.12 There are two mechanisms 
that give rise to genomic instability and 
lead to CRC: chromosome instability 
(cromosomal instability or CIN) and 
microsatellite instability (MIN).13-15 The 
beginning of the process of colon cancer 
occurring involving somatic mutations 
After TACI
Before TACI
275
J Med Sci, Volume 51, Number 3, 2019 July: 270-281
occurs in the adenomatous polyposis coli 
(APC) genes which subsequently develop 
into adenomas. The transition from 
adenoma to carcinoma is the result of a 
mutation of the p53 tumor suppressor 
gene that is the ultimate transformation 
to malignancy.13-15
Radiology imaging 
Imaging on the CRC is divided into 
imaging for diagnosis, tumor stage 
and therapeutic evaluation. American 
College of Radiology recommends 
modalities used for diagnosis with DCBE 
modalities, flexible sigmoidoscopy, 
colonoscopy and CT colonography.5 
Staging is recommended with modalities 
of CT scan and magnetic resonance 
imaging (MRI).4,6,18 While evaluation of 
therapy and metastasis detection using 
CT scan, MRI and positron emission 
tomography - computed tomography 
(PET-CT) modalities.4,6,18
The morphology of CRC images in 
DCBE examination can be seen as a 
description of filling defect in the form 
of sessile or pedunculated, exophytic, 
circumferential (apple core), ulceration 
or desmoplasic.19 Flexible sigmoidoscopy 
is safer, faster, more tolerable and does 
not require sedation, but requires 
follow-up colonoscopy because it cannot 
detect lesions in the proximal colon.20 
Colonoscopy has been considered as 
a gold standard for early detection of 
CRC, because its sensitivity is 96.7% 
and its specificity is 98% for detecting 
colon polyps as well as possible for 
polypectomy actions which are then sent 
for histopathological examination.19,20 
CT colonography or non-invasive virtual 
colonoscopy that produces a two-
dimensional image to identify lesions 
in the colon and a three-dimensional 
reconstruction image that produces 
a prospective image of endoluminal 
colon and rectum.4,16,20-25Compared with 
colonoscopy, CT colonography is safer, 
more precise at and cheaper with the 
effectiveness of similar results, while 
the shortage does not allow biopsy or 
removal of polyps.4,23-25
CT scans are widely used to assess 
preoperative tumor stage, extension of 
tumor to surrounding tissue, metastasis, 
vascular abnormalities and possible 
complications of surgery or tumor 
complications.19,26 In CT, the CRC is usually 
seen as soft tissue mass constricting the 
colon lumen and may also manifest 
as focal thickening of the colon walls 
and narrowing of the lumen.26 A meta-
analysis study showed that the sensitivity 
and specificity differentiating between 
T1/T2 versus T3/T4 were 86% and 78% 
respectively.27MRI was the most accurate 
modality for CRC staging, its accuracy 
ranged between 84% - 90% .4,19MRI is 
recommended as a standard modality 
for preoperative staging.28,29
Assessment of the evaluation of 
the CRC treatment response was based 
on the criteria for response evaluation 
criteria in solid tumors (RECIST) based 
on tumor size reduction as measured by 
anatomical imaging modalities such as 
CT scan or MRI (TABLE 1).30.31Dynamic 
contrast enhanced CT (DCE-CT) becomes 
a valid technique for assessing tumor 
angiogenesis and monitoring disease 
control after local-regional therapy.30 
Dynamic contrast-enhancedMRI (DCE-
MRI) and DWI are useful for evaluation 
of post-chemotherapy responses which 
show biological effects and functional 
treatment, as an early sign of therapeutic 
response because cell apoptosis, anti-
angiogenesis can be detected before 
tumor size changes from 2 weeks post-
therapy.4,28-30PET-CT becomes a valuable 
modality for assessing neoadjuvant 
post-chemoradiotherapy response, 
with metabolic responses early on FDG 
PET allows for a change in therapeutic 
management.32 PET-CT FDG has been 
shown to be superior in accuracy in 
metastatic nodal assessment, hepatic 
metastasis detection and extracellic 
metastases.32
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TABLE 1. RECIST response criteria, version 1.1 31
Level of Response Criteria of Response
Complete response Loss of all target lesions. All pathologic lymph nodes  (target or non-
targeted) should have a short axis reduction of <10 mm
Partial response Decrease ≥ 30% of the target diameter of the target lesion, using the 
longest diameter as the reference base.
Progressive disease Increased ≥ 20% of the target diameter of the lesion, the presence of 
one or more new lesions is also considered progressive disease
Stable disease Depreciation that is not eligible for partial response or an increase 
that is not eligible for progressive disease
Stadium 
Stage CRC can be conducted by 
using two systems. The traditional 
system according to Dukes that has 
been largely superseded by the TNM 
system published by the American Joint 
Committee on Cancer (AJCC) (TABLE 2), 
but is still frequently used clinically. This 
staging system is related to the prognosis 
and 5-year life expectancy of the patient. 
Recommended using a TNM staging 
system with a modified Aston-Coller 
Dukes system (TABLE 3).16,17
TABLE 2. TNM classification system for colorectal cancer stage according to AJCC 
edition717
Classification Definition of TNM classification
T - Primary tumor 
Tx  Primary tumor can not be assessed
T0  There is no primary tumor
Tis In situ carcinoma, invasion of lamina propia or intraepitelial 
T1 Invasion of tumors in the sub-mucous layer
T2 Invasion of tumors in the muscle layer of propria
T3 The invasion of the tumor passes through the propria 
muscle to the subserosa or into the pericone pericardial pericardial 
pericardial tissue
T4a Penetration of the tumor to the surface of the visceral peritoneum
T4b Invasion of the tumor directly or following against the organ or the 
surrounding structure 
N-Regional lymph nodes
Nx Regional lymph nodes can not be assessed
N0 No regional lymph nodes were obtained
N1 Metastasis in 1-3 regional lymph nodes
N1a  Metastasis in a regional lymph node
N1b Metastasis in 2 - 3 regional lymph nodes
N1c Tumor deposits on the subserosa, mesentery, or pericoly or perirectal 
tissue that are not coated peritoneum without regional lymph node 
metastases
N2 Metastasis in 4 or more regional lymph nodes
N2a Metastasis in 4 to 6 regional lymph nodes
N2b Metastasis in 4 or more regional lymph nodes
M - Remote metastases
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M0 There is no distant metastasis
M1 There is a distant metastasis
M1a Metastasis is limited to one organ or place (eg, liver,pulmo, ovary, non-
regional lymph nodes)
M1b Metastasis in more than one organ or place or peritonium
TABLE3. Colorectal cancer stage based on TNM system with 
Dukes system modified by Astler-Coller33
Stadium T N M Dukes MAC
0 Tis N0 M0 - -
I T1 N0 M0 A A
T2 N0 M0 A B1
IIA T3 N0 M0 B B2
IIB T4a N0 M0 B B2
IIC T4b N0 M0 B B3
IIIA T1-T2 N1/N1c M0 C C1
T1 N2a M0 C C1
IIIB T3-T4a N1/N1c M0 C C2
T2-T3 N2a M0 C C1/C2
T1-T2 N2b M0 C C1
IIIC T4a N2a M0 C C2
T3-T4a N2b M0 C C2
T4b N1-N2 M0 C C3
IVA Ant T Any N M1a - -
IVB Ant T Any N M1b - -
MAC is an Astler-Coller modification classification
Management 
The management of the CRC is 
multidisciplinary involving several 
specializations/subspecialties including 
gastroenterology, gastroenterology 
surgery, medical oncology, and 
radiotherapy. Surgical therapy is a major 
modality for early stages with curative 
goals. Chemotherapy is the first choice of 
advanced cancer with palliative goals.9,10 
The standard chemotherapy regimen of 
either adjuvant or palliative is FOLFOX 
consisting of 5-fluorouracil, leucovorin 
and oxaliplatin. Targeted therapy has 
grown rapidly and can be given in a 
variety of clinical situations, either as 
a single drug or a combination with 
other therapeutic modalities. Targeted 
therapy commonly used for CRC is 
bevacizumab, which is an alternative 
regimen for adjuvant therapy for stage 
III CRC and palliative therapy at stage IV, 
in combination with FOLFOX.5,18
REVIEW OF TACI
TACI is a minimally invasive 
technique in the field of interventional 
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radiology in conducting locally-guided 
fluoroscopy therapy for treatment 
in patients with primary tumors and 
metastases.6 The purpose of this therapy 
is to kill tumor cells by infusion of 
chemotherapy via arterial catheter 
selectively on arterial feeding which 
supplies blood to the tumor, resulting 
in maximum concentration and uptake 
of the drug in the target organ and 
increased therapeutic response with 
minimal systemic side effects.6,33,34
The TACI technique has been 
shown to kill tumor cells more strongly 
than conventional chemotherapy 
techniques, and shows an increase in 
life expectancy in some studies.6 With 
the digital substraction angiographic 
(DSA) technique in TACI it is possible to 
evaluate the therapeutic response by 
measuring staining and vascularization 
tumors in arterial feeding.6 An imaging 
evaluation is usually performed 4-6 
weeks after therapy, and the maximum 
therapeutic response is usually seen 3-4 
months after therapy.6 This unique TACI 
therapy characterization provides an 
attractive therapeutic option in patients 
who previously had several alternative 
treatment options.6
DISCUSSION
The development of diagnostic and 
therapeutic techniques in the current 
CRC management is highly variable 
and heterogeneous. The options and 
recommendations of CRC therapy depend 
on the stadium, histopathology, possible 
side effects, patient condition and 
patient preferences, allowing multiple 
alternative options to the patient.
In this case the patient is an 80-year-
old woman with a history of colon 
polyps with clinical symptoms of bloody, 
red, slimy and smelly bowel movements 
accompanied by defecating habits, 
weight loss and having a habit of eating 
fatty foods but lacking fiber foods. From 
age, risk factors, and clinical symptoms 
that strongly lead to the diagnosis of CRC.
The diagnosis of this case used DBCE 
and colonoscopy modalities, where in 
DCBE a filling defect of pedunculated 
form was found and in colonoscopy the 
tumor was detected in the sigmoid pars 
proximal colon. The DCBE was chosen 
because it is non-invasive while the 
colonoscopy is chosen because it is a 
gold standard and biopsy for anatomical 
pathology is examined.19,20 The location 
of the tumor is in the sigmoid, which is 
the second largest site after the rectum.35
In this case, histopathologic 
examination results were concluded as 
a good adenocarcinoma differentiation. 
95% CRC is an adenocarcinoma derived 
from colonic polyps that develop into 
cancer, where in general the prognosis is 
quite good.36
Determination of staging in this 
case by CT scan examination to assess 
tumor extension to neighboring tissues, 
metastases, vascular abnormalities and 
tumor complications.26 CT scan results 
show a proximal sigmoid tumor 9.1 x 8.3 
x 7.4 cm accompanied by severe lumen 
colon narrowing, with invasion of the 
subserosa and mesenterial fat with a fat 
stranding image but no infiltration to 
the surrounding tissue, but metastatic 
nodules on the pericolon, invisible 
metastases of the liver. It was concluded 
that this patient was included in T3N1M0 
stage IIIB based on AJCC.
The choice of CRC therapy at stage 
IIIb according to the ESMO Consensus 
Guidelines is wide surgical resection 
with anastomosis followed by adjuvant 
chemotherapy after surgery.5 In this case 
because the patient refuses to undergo 
surgery it is considered as unresectable 
adenocarcinoma colorectal, so it is 
decided to take chemotherapy treatment 
with TACI procedure for therapy palliative 
with a combination of Oxaliplatin and 
Bevacizumab in three procedures every 
2 months. Selection of TACI therapy 
due to the unique characteristics of 
therapy proven capable of lethal tumor 
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cells is stronger than conventional 
chemotherapy techniques, and shows an 
increase in life expectancy.6 In addition, 
TACI allows for simultaneous evaluation 
of treatment.33
In the evaluation of therapy with 
screening of arteriography, there 
was a decrease in tumor staining and 
vascularization on arterial feeding from 
the first TACI to the third TACI. While 
the CT scan evaluated the size of the 
tumor shrank to 2.13 cm x 4.92 cm x 4.35 
cm and there was no infiltration to the 
surrounding tissue or metastatic nodules 
and distant metastases on heparset after 
the third TACI action, based on RECIST 
categorized partial response and at the 
re-staging assessment has decreased the 
stage to T3N0M0 stage IIA.
This proves that the management 
of CRC in this case, TACI therapy using 
Oxaliplatin and Bevacizumab infusions 
in three procedures is quite effective 
as palliative therapy. However further 
studies should be undertaken to verify 
these findings.
CONCLUSION
Choosing the right radiological 
imaging modalities in diagnosis, staging 
and treatment evaluation is crucial in 
CRC management that can assist in the 
choice of therapy, treatment success and 
survival rate of CRC patients.We reported 
the case of a woman with unresectable 
adenocarcinoma colorectal who showed 
good results after receiving TACI therapy 
in the form of partial response, decreased 
stage, disappearance of clinical 
symptoms and improvement of quality 
of life without systemic side effects.
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